Eisai Divests US Rights to CTCL Therapy Targretin® to Valeant

Abstract

Valeant Pharmaceuticals International has acquired US rights to the capsule and gel formulations of Targretin® (bexarotene), which is used to treat skin problems arising from cutaneous T-cell lymphoma, from Eisai for US$65 M upfront plus contingent payments based on certain undisclosed milestones. Eisai, which acquired Targretin from Ligand Pharmaceuticals in 2006, will retain rights outside of the US and will continue to supply product to its sales subsidiaries and distribution partners.